MedTrace Logo

Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

NCT01344044 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2017-03-30

No results posted yet for this study

Summary

This study aims to examine the efficacy of a brain-computer interface system for the treatment of inattentive symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The investigators hypothesis is that children with ADHD receiving treatment with the BCI-based training will improve to a greater extent than the control group.

Additionally, the investigators are also conducting an fMRI study involving interested participants, to elucidate the neural mechanisms underlying any behavioural improvement. This is necessary to help the investigators gain a better picture of brain correlates related to ADHD and understand how the intervention can affect the brain.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DEVICE

BCI

24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.

Sponsors & Collaborators

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • Agency for Science, Technology and Research

    collaborator OTHER

  • Singapore Clinical Research Institute

    collaborator OTHER

  • National Healthcare Group, Singapore

    lead OTHER_GOV

Principal Investigators

  • Choon Guan Lim · Institute of Mental Health, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2016-05-13
Completion
2016-05-13

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01344044 on ClinicalTrials.gov